Detalhe da pesquisa
1.
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Mol Pharmacol
; 92(6): 694-706, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28974538
2.
BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.
bioRxiv
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38559135
3.
Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2.
ACS Omega
; 6(33): 21327-21338, 2021 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34471737
4.
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Clin Cancer Res
; 27(17): 4923-4936, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34145028
5.
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Clin Cancer Res
; 26(20): 5338-5347, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32694156
6.
Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN.
Mol Biol Cell
; 14(12): 4813-25, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12960424
7.
Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX.
Oncogene
; 24(38): 5837-49, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897874
8.
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
Atherosclerosis
; 236(1): 91-100, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25016363
9.
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
PLoS One
; 8(12): e83190, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24391744